Neuren Pharmaceuticals LimitedASX: NEU

Neuren receives Rare Pediatric Disease Designation from FDA

· Issued by Neuren Pharmaceuticals Limited

Filed with ASX · · 1 page · English

Summary by 6ix AI

This designation may allow Neuren to obtain a priority review voucher if the program is reauthorized and the drug receives marketing authorization. Neuren is focused on developing therapies for serious neurological disorders with limited treatment options, and has previously received similar designations for other conditions.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Neuren Pharmaceuticals Limited on 6ix

Earlier from Neuren Pharmaceuticals

Later from Neuren Pharmaceuticals

All Neuren Pharmaceuticals news releases